<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[CoVIg-19 Plasma Alliance 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=37393></link><description><![CDATA[CoVIg-19 Plasma Alliance 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sat, 16 May 2026 12:56:24 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2021/04/12_3554238800_20210405093815_8496872701.jpg]]></url></image><language>ko-KR</language><item><title><![CDATA[CoVIg-19 Plasma Alliance Announces Topline Results from NIH-Sponsored Clinical Trial of Investigational COVID-19 Hyperimmune Globulin Medicine]]></title><link>https://www.newswire.co.kr/newsRead.php?no=921076</link><description><![CDATA[OSAKA, Japan & KING OF PRUSSIA, Pa.--(Business Wire/Korea Newswire)--The CoVIg-19 Plasma Alliance today announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its endpoints. No serious safety signals were raised ...]]></description><pubDate>Mon, 05 Apr 2021 10:10:00 +0900</pubDate></item><item><title><![CDATA[코로나19 혈장치료제 개발 얼라이언스, NIH 후원 연구용 코로나19 고면역성 글로불린 약물 임상 시험의 중대 결과 발표]]></title><link>https://www.newswire.co.kr/newsRead.php?no=921077</link><description><![CDATA[오사카, 일본/킹 오브 프러시아, 펜실베이니아--(Business Wire/뉴스와이어)--미국 국립보건원(NIH) 산하 국립알레르기감영병연구소(NIAID)가 후원하고 연구비를 지원한 ITAC(Inpatient Treatment with Anti-Coronavirus Immunoglobulin) 임상 제3상 시험이 평가지표를 충족하지 못했다고 코로나19 혈장치료제 개발 얼라이언스(CoVIg-19 Plasma Alliance)가 2일 발표했다.   시험에서 심각한 안전성 실마리 정보는 나타나지 않았다.  이 연구는 중증 합...]]></description><pubDate>Mon, 05 Apr 2021 10:10:00 +0900</pubDate></item></channel></rss>